Navigation Links
Martek Signs Multi-Year Infant Formula License and Supply Agreement with Alter Farmacia

COLUMBIA, Md., Oct. 5 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation announced today that it has entered into a multi-year license and supply agreement with Alter Farmacia, S.A. for the inclusion of Martek's arachidonic acid (ARA) oil in Alter's infant formula products. Under the terms of the agreement, Alter Farmacia will purchase Martek's ARA for all of its infant formula products that contain ARA sold in Spain and Portugal.

Headquartered in Spain, Alter Farmacia is part of the Alter Group and markets baby foods, infant formula, and cosmetics.

Naturally present in human breast milk, ARA is an essential fatty acid important to infant development and growth. When used in combination with DHA, clinical studies have demonstrated numerous benefits for infants receiving ARA supplemented formula. Martek's ARA is the only ARA currently used in U.S. infant formulas, and is present in more than 90 percent of infant formula sold in the U.S.

"This product launch is another step towards Martek's goal of further expanding our infant formula market outside of the U.S., where we are already in more than 90 percent of infant formulas sold," said Steve Dubin, CEO of Martek. "It's satisfying to know that with every new license agreement, more and more infants around the world will benefit from Martek's products."

Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation and development of DHA omega-3 products that promote health and wellness through every stage of life. The company produces life'sDHA(TM), a sustainable and vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in foods, beverages, infant formula, and supplements. The company also produces life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, from a sustainable, vegetarian source, for use in infant formula. For more information on Martek Biosciences Corporation, visit

Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2006 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.


Cassie France-Kelly

Public Relations

(443) 542-2116

Kyle Stults

Investor Relations

(410) 740-0081

SOURCE Martek Biosciences Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Filtration treatment assigns more live kidney donation
2. Depressed women show signs of earlier onset of Perimenopause
3. More signs to an approaching migraine attack
4. An Indian Bride with signs of SARS
5. Recognize Heart Attack Signs
6. Parents Should Look For Signs Of Children Becoming Overweight
7. Early Warning Signs Of Heart Disease
8. Warning Signs On Powered Baby Milk
9. Genetical Screening Can Detect Early Signs Of Multiple Sclerosis
10. Diagnosis of Alzheimers years before clinical signs emerge
11. President and Founder of National Obesity Forum Resigns
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... of the most popular and least understood books in the Holy Scriptures, Revelation. The ... that have baffled scholars for centuries. Many have tossed it off as mere rubbish, ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile app ... struggle to reverse the tide of prescription drug addiction. The ... their medicine intake and stepping down their dosage in a ... launch in December 2017; the first 100,000 people to sign ... at ...
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
Breaking Medicine Technology: